Evidence map›Paper›PMID 35770317›Full record

ArticleExperimental dermatology2022

Effects of mucopolysaccharide polysulphate on tight junction barrier in human epidermal keratinocytes.

Mika Fujikawa, Hiroko Sugimoto, Rie Tamura, Koki Fujikawa, Ami Yamagishi, Yuhki Ueda

Open access · hybridAbstract read
In one paragraph

Article in Experimental dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Use of a Silkworm (Nutrients · 2023
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mika FujikawaKyoto R&D Center, Maruho Co., Ltd., Kyoto, Japan.ORCID 0000-0003-0159-9708
Hiroko SugimotoKyoto R&D Center, Maruho Co., Ltd., Kyoto, Japan.ORCID 0000-0003-0591-7451
Rie TamuraKyoto R&D Center, Maruho Co., Ltd., Kyoto, Japan.ORCID 0000-0002-3096-8683
Koki FujikawaKyoto R&D Center, Maruho Co., Ltd., Kyoto, Japan.ORCID 0000-0001-8915-8565
Ami YamagishiKyoto R&D Center, Maruho Co., Ltd., Kyoto, Japan.ORCID 0000-0002-7483-7941
Yuhki UedaKyoto R&D Center, Maruho Co., Ltd., Kyoto, Japan.ORCID 0000-0001-5009-5245
Maruho (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tight junctions (TJs) play important roles in epidermal barrier function and their dysfunction is involved in the pathogenesis of various skin diseases, including atopic dermatitis (AD). Mucopolysaccharide polysulphate (MPS) is the active ingredient of a moisturizing agent used to treat xerosis in patients with AD; however, its mechanism of action on TJ barrier function remains unclear. To elucidate the effects of MPS on TJs, adult human epidermal keratinocyte (HEKa) cells were exposed to MPS, subjected to Western blotting and quantitative PCR analyses for the investigation of TJ-related factors. MPS treatment significantly increased the mRNA and protein expression of claudin-1 (CLDN1) and zonula occludens-1, and significantly increased transepithelial electrical resistance (TEER), which indicates TJ integrity. Conversely, the sulphated and non-sulphated glycosaminoglycans, chondroitin sulphate and hyaluronic acid, respectively, had little effect on TEER or the expression of mRNAs or TJ-related proteins. Interestingly, MPS treatment also inactivated the extracellular signal-regulated kinase signalling pathway, which is known to negatively regulate CLDN1 expression. Furthermore, MPS notably improved the reduction in CLDN1 expression and TEER caused by histamine, which is upregulated in the skin of patients with AD and is known to disrupt the TJ barrier function. Taken together, these findings demonstrate that treatment with the moisturizing agent, MPS, can repair TJ dysfunction and could therefore represent a new therapeutic option for treating patients with AD.

Indexed as

Dermatitis, AtopicTight JunctionsAdultClaudin-1EpidermisGlycosaminoglycansHumansKeratinocytesClaudin-1Glycosaminoglycansmucopolysaccharide polysulfateclaudin-1heparinoidmucopolysaccharide polysulphateskin barriertight junction

Identifiers

PMID35770317
PMCPMC9796026
OpenAlexW4283743479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.